Security
Profound Medical Corp. · PRN
PRNTSXCommon stockCurrentCIK 1628808Updated Oct 12, 2026
PRN price & chart
Loading TradingView…
TSX:PRN on TradingView ↗About the company
Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO ®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and…
In the news
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President ↗
Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’ ↗
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow ↗
Seeking Alpha
Profound Medical: Q3 Revenue Beats Outlook (Rating Upgrade) ↗
Profound Medical names interim CFO ↗
Profound reiterates ~$25M 2026 revenue outlook as CMS proposes 14.9% OPPS payment increase to $15,494 per TULSA procedure ↗
SEC disclosures
Profound Medical Corp. files 8-K: Material Event ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 77,475,000Source | 70,234,000Source | 43,911,000Source | 64,421,000Source |
| Property, Plant and Equipment, NetUSD | 698,000Source | 425,000Source | 909,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 59,723,000Source | 54,912,000Source | — | — |
| Inventory, NetUSD | 8,238,000Source | 5,801,000Source | — | — |
| Assets, CurrentUSD | 76,089,000Source | 69,065,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 184,000Source | 396,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 11,041,000Source | 9,812,000Source | 12,731,000Source | 12,417,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 323,839,000Source | 281,552,000Source | — | — |
| Additional Paid in CapitalUSD | 25,310,000Source | 21,298,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -287,740,000Source | -245,170,000Source | — | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 5,025,000Source | 2,742,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 66,434,000Source | 60,422,000Source | — | — |
| Liabilities and EquityUSD | 77,475,000Source | 70,234,000Source | — | — |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,075,000Source | 6,565,000Source | — | — |
| Operating Lease, Liability, CurrentUSD | 213,000Source | 257,000Source | — | — |
| Accounts Payable, CurrentUSD | 1,563,000Source | 1,317,000Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | — | 203,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 79,000Source | 71,000Source | — | — |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 445,000Source | 419,000Source | — | — |
| DeferredTaxLiabilitiesUSD | — | — | 59,000Source | — |
| IntangibleAssetsOtherThanGoodwillUSD | — | — | 490,000Source | 680,000Source |
| IssuedCapitalUSD | — | — | 217,393,000Source | 205,825,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 4,499,000Source | — | — | — |
| Long-term Debt, Current MaturitiesUSD | — | 1,737,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 4,499,000Source | 2,924,000Source | — | — |
| TradeAndOtherCurrentReceivablesUSD | — | — | 7,288,000Source | 6,344,000Source |
| TradeAndOtherReceivablesUSD | — | — | 7,288,000Source | 6,344,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -42,570,000Source | -27,816,000Source | -28,569,000Source | -28,669,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,490,000Source | 2,581,000Source | — | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 2,822,000Source | -656,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | 21,000Source | -146,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -38,207,000Source | -23,453,000Source | — | — |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -242,000Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 176,000Source | — | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 41,138,000Source | 54,696,000Source | — | — |
| Repayments of Long-term DebtUSD | 290,000Source | 2,560,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 59,723,000Source | 54,912,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 132,000Source | 252,000Source | — | — |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | — | — | -956,000Source | -1,424,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | — | 3,417,000Source | 4,238,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | 20,000Source | -1,905,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 5,490,000Source | 2,581,000Source | — | — |
| Amortization of Intangible AssetsUSD | 187,000Source | 229,000Source | — | — |
| DepreciationUSD | 373,000Source | 707,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,134,000Source | 3,808,000Source | — | — |
| GeneralAndAdministrativeExpenseUSD | — | — | 9,168,000Source | 9,465,000Source |
| Income Tax Expense (Benefit)USD | 252,000Source | -2,000Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesUSD | — | — | 669,000Source | — |
| Inventory Write-downUSD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -42,570,000Source | -27,816,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 42,570,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -1,064,000Source | 5,244,000Source | — | — |
| Operating ExpensesUSD | 52,647,000Source | 40,099,000Source | — | — |
| Operating Lease, Lease IncomeUSD | — | 940,000Source | — | — |
| Payments of Financing CostsUSD | 1,016,000Source | 4,895,000Source | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | 292,000Source | 312,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | 7,273,000Source |
| Proceeds from Issuance of Common StockUSD | 42,436,000Source | 62,106,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 8,000Source | 45,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 9,740,000Source | — | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 32,051,000Source | 23,134,000Source | — | — |
| Operating Income (Loss)USD | -41,254,000Source | -33,062,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -42,318,000Source | -27,818,000Source | — | — |
| Income Tax Expense (Benefit)USD | 252,000Source | -2,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -42,570,000Source | -27,816,000Source | — | — |
| Earnings Per Share, BasicUSD per share | 1.41Source | 1.12Source | — | — |
| Earnings Per Share, DilutedUSD per share | 1.41Source | 1.12Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 30,232,966Source | 24,765,503Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 30,232,966Source | 24,765,503Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 187,000Source | 229,000Source | — | — |
| ApplicableTaxRatenumber | — | — | 0.26Source | 0.25Source |
| BasicEarningsLossPerShareUSD per share | — | — | 1.35Source | 1.38Source |
| Current Income Tax Expense (Benefit)USD | 231,000Source | 144,000Source | — | — |
| CurrentTaxExpenseIncomeUSD | — | — | -187,000Source | — |
| DeferredTaxExpenseIncomeUSD | — | — | 59,000Source | — |
| DepreciationAndAmortisationExpenseUSD | — | — | 1,146,000Source | 1,604,000Source |
| DepreciationRightofuseAssetsUSD | — | — | 217,000Source | 228,000Source |
| DilutedEarningsLossPerShareUSD per share | — | — | 1.35Source | 1.38Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | — | — | 3,417,000Source | 4,238,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,134,000Source | 3,808,000Source | — | — |
| GeneralAndAdministrativeExpenseUSD | — | — | 9,168,000Source | 9,465,000Source |
| Gross ProfitUSD | 11,393,000Source | 7,037,000Source | 4,382,000Source | 3,021,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillUSD | — | — | — | 2,524,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -43,370,000Source | -28,286,000Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | — | -128,000Source | 287,000Source |
| InterestExpenseUSD | — | — | 146,000Source | 290,000Source |
| Interest Expense, DebtUSD | 394,000Source | — | — | — |
| InterestExpenseOnLeaseLiabilitiesUSD | — | — | 43,000Source | 59,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 1,070,000Source | 1,436,000Source | — | — |
| Marketing and Advertising ExpenseUSD | 3,856,000Source | 4,478,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 42,570,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -1,064,000Source | 5,244,000Source | — | — |
| Operating ExpensesUSD | 52,647,000Source | 40,099,000Source | — | — |
| Operating Lease, Lease IncomeUSD | — | 940,000Source | — | — |
| ProfessionalFeesExpenseUSD | — | — | 5,820,000Source | 4,146,000Source |
| ProfitLossBeforeTaxUSD | — | — | -28,697,000Source | -28,382,000Source |
| ProfitLossFromOperatingActivitiesUSD | — | — | -28,616,000Source | -32,126,000Source |
| Research and Development ExpenseUSD | 20,596,000Source | 16,965,000Source | 14,377,000Source | 14,690,000Source |
| RevenueUSD | — | — | 7,199,000Source | 6,681,000Source |
Offerings
Registration 333-295811
Filing attachments
tm2614840d1_ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 tm2614840d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 13, 2026 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 2, 2026 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual and special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (“Common Shares”) in the capital of Profound Medical Corp. (t…
Read attachment ↗prof-20251231xex4d1.htm · 10-K · 2026-03-05
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of filing of our Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report on Form 10-K”), Profound Medical Corp. (“Profound,” the “Company,” “we,” “us” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares, no par value (“Common Shares”). The following descri…
Read attachment ↗tm2534550d1_ex99-1.htm · 8-K · 2025-12-31
EX-99.1 3 tm2534550d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Profound Medical Corp. Announces Closing of Private Placement TORONTO, December 30, 2025 - Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”). Pursuant to the Offering, the Company issued an aggregate of 921,428 common shares at a price of US$7.00 per common share,…
Read attachment ↗tm2533900d1_ex99-1.htm · 8-K · 2025-12-19
EX-99.1 5 tm2533900d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, December 19, 2025 - Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a p…
Read attachment ↗